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Levamisole is an antihelminthic and immunomodulator medication that was banned by the USFDA in 1998. It has been increasingly
used to adulterate cocaine due to its psychotropic effects and morphological properties. Adverse reactions including cutaneous
vasculitis, thrombocytopenia, and agranulocytosis have been well described. Despite systemic vasculitis in this setting, renal
involvement is uncommon. We report here a case of ANCA positive systemic vasculitis with biopsy proven immune complex
mediated glomerulonephritis likely secondary to levamisole/cocaine. A 40-year-old Caucasian male with no past medical history
presented with 3-week history of fatigue, skin rash, joint pains, painful oral lesions, oliguria, hematuria, worsening dyspnea on
exertion, and progressive lower extremity edema. He had a history of regular tobacco and cocaine use. Lab testing revealed severe
anemia, marked azotemia, deranged electrolytes, and 4.7 gm proteinuria. Rheumatologic testing revealed hypocomplementemia,
borderline ANA, myeloperoxidase antibody, and positive atypical p-ANCA. Infectious and other autoimmune workup was negative.
Kidney biopsy was consistent with immune mediated glomerulonephritis and showed mesangial proliferation and immune
complex deposition consisting of IgG, IgM, and complement. High dose corticosteroids and discontinuing cocaine use resulted
in marked improvement in rash, mucocutaneous lesions, and arthritis. There was no renal recovery and he remained hemodialysis
dependent.

1. Introduction
Levamisole is an antihelminthic and immunomodulator
medication previously used to treat steroid resistant
nephrotic syndrome in pediatric population and also as
adjuvant chemotherapy for colorectal and breast cancer
[1, 2]. It was banned by USFDA in 1998 due to serious side
effects including nonspecific rash, thrombocytopenia, and
agranulocytosis. It was associated with reversible cutaneous
vasculitis with earliest cases reported in 1970s [3, 4].
Particularly striking feature in these cases was purpura
involving the ear. More recently, it has increasingly been
used as a cutting agent in cocaine especially in the United
States. Nearly 69% of cocaine samples seized by the Drug
Enforcement Administration (DEA) in 2008-2009 tested
positive for adulteration [5]. Renal involvement in the form

of glomerulonephritis is relatively uncommon. We describe
here a case of ANCA positive systemic vasculitis with biopsy
proven immune complex mediated glomerulonephritis
secondary to levamisole/cocaine, a rare entity.

2. Case Presentation
A 40-year-old Caucasian male with no past medical history
presented to the emergency room with one-week history of
progressive shortness of breath on exertion. He also complained of palpitations, fatigue, and orthopnea. In addition,
he complained of progressive lower extremity swelling for the
last 3 weeks and multiple painful ulcerations on his tongue
and in his mouth for 2 weeks. History was also notable for
multiple joint pains for 6 months. He was diagnosed with
Lyme’s disease and was treated with high dose doxycycline for
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Table 1: Lab results.

Variable
White cell count
Neutrophils %
Lymphocytes %
Eosinophils %
Basophils %
Monocytes %
Hemoglobin, g/dL
Platelet count
Sodium mmol/L
Potassium mmol/L
Chloride mmol/L
Carbon dioxide mmol/L
Blood urea nitrogen mg/dL
Creatinine mg/dL

Result on
admission
(reference
range)
12.7 (3.5–10.1)
10.8 (1.6–7.2)
1.4 (1.1–4.0)
0.1 (0.0–0.4)
0.1 (0.0–0.1)
0.3 (0.0–0.9)
6.1 (13.5–17.0)
334 (150–400)
120 (135–145)
6.9 (3.5–5.2)
87 (95–107)
10 (21–31)
195 (8–22)
20.83
(0.60–1.40)∗
5.6 (8.5–10.5)
20.2 (2.3–4.3)

Calcium mg/dL
Phosphorus mg/dL
Aspartate aminotransferase,
721 (10–37)
U/L
Alanine aminotransferase,
252 (9–47)
U/L
Alkaline phosphatase, U/L
146 (30–110)
Total bilirubin, mg/dL
0.8 (0.3–1.2)
Albumin, g/dL
2.9 (3.5–5.1)
Protein, g/dL
5.3 (6.4–8.6)
International normalized
1.7
ratio
Partial thromboplastin time,
44.1 (25.0–32.0)
sec
Urine protein/creatinine
4.7 (0.0–0.2)
ratio
3+ protein, 2+
blood, 10–20
Urinalysis
RBC, and
Hyaline and
RBC cast
ESR, mm/hr
61 (0–20)
CRP mg/dL
7.4 (0.0–1.0)
Complement C3, mg/dL
42 (70–176)
Complement C4, mg/dL
7.7 (12.1–42.9)
Anti-nuclear antibodies,
<1 : 160 (<1 : 160)
IU/mL
Anti-double-stranded DNA,
6.6 (0.0–29.9)
IU/mL
Anti-neutrophil cytoplasmic 1 : 640 p-ANCA
antibody
(<1 : 20)
Anti-SSA, U
0.9 (<20)
Myeloperoxidase antibody, U
2.8 (<0.4)
Proteinase-3 auto antibody,
0.4 (<0.4)
U
Cryoglobulin screen
Negative

Table 1: Continued.
Result at
discharge
(reference
range)
5.7 (3.5–10.1)
4.6 (1.6–7.2)
0.8 (1.1–4.0)
0.0 (0.0–0.4)
0.0 (0.0–0.1)
0.3 (0.0–0.9)
9.4 (13.5–17.0)
267 (150–400)
138 (135–145)
4.6 (3.5–5.2)
100 (95–107)
24 (21–31)
67 (8–22)

Variable
Lupus anticoagulant
Serum and protein
electrophoresis
Tuberculin skin test
HIV-1 and HIV-2 antibodies
Acute hepatitis panel
Rapid plasma reagin
Histoplasma urine antigen
Blood and urine cultures
∗

Result on
admission
(reference
range)
Negative
Negative for
monoclonal
antibodies
Negative
Negative
Negative for
hepatitis B and
hepatitis C
Negative
Negative
Negative

Result at
discharge
(reference
range)

No serum creatinine values were available prior to admission.

6.77 (0.60–1.40)
8.6 (8.5–10.5)
5.8 (2.3–4.3)
39 (10–37)
62 (9–47)
113 (30–110)
0.3 (0.3–1.2)
3.4 (3.5–5.1)
5.3 (6.4–8.6)
1.1
28.8 (25.0–32.0)

Negative
(<1 : 160)

2 months. Two months prior to admission, he noticed diffuse
nonitchy rash on his chest, back, abdomen, arms, and legs
that subsequently resolved. One month prior to admission,
he noticed decreased urine output and dark colored urine.
There was no history of fever, chills, weight loss, night sweats,
cough, chest pain, or hemoptysis. He denied having any dry
eyes, oral ulcers, photosensitivity, abdominal pain, hematuria, dysuria, or neurologic symptoms.
Medications included doxycycline and ibuprofen. He had
history of long standing tobacco abuse, alcohol use, and regular cocaine use. He denied having any tattoos, sick contacts,
recent travel, or environmental or occupational exposure.
On examination, he was afebrile, tachycardic, tachypneic,
and hypoxic on room air. The tongue had hyperkeratotic,
hyperpigmented papules. There were scattered erythematous
maculopapular lesions on the chest. He had bilateral lower
extremity edema with skin changes suggestive of chronic
venous stasis and prominent symmetric synovitis of metacarpophalangeal and wrist joints. Chest auscultation revealed
diffuse rales bilaterally. Cardiovascular, abdominal, and neurologic examinations were unremarkable.
Lab results are shown in Table 1. Notable lab abnormalities included anemia and severe azotemia with multiple
electrolyte abnormalities (no records of prior serum creatinine values). Urinalysis showed significant hematuria and
proteinuria. Urine protein/creatinine ratio was 4.7. Acute
phase reactants ESR and CRP were elevated. BNP and PTH
were also elevated. Rheumatologic testing revealed borderline ANA, positive atypical p-ANCA (1 : 640), and positive
anti-myeloperoxidase antibodies. Complement levels (C3
and C4) were low. Remainder of the rheumatologic workup
was negative. Chest X-ray showed pulmonary edema. Urine
screen for drugs returned positive for cocaine and levamisole.
Unfortunately quantification of levamisole could not be
performed on time and resulted negative.
Kidney biopsy showed diffuse tubulointerstitial fibrosis
with the majority of glomeruli globally sclerosed. Few intact
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(a)

(b)

(c)

(d)

Figure 1: (a) Masson trichrome stain (100x) revealed severe interstitial fibrosis, thickened arterioles, and mild proliferation of glomeruli.
(b) PAS stain (600x) showed mild mesangial proliferation and segmental sclerosis. No extra capillary crescent or necrosis was identified. Six
of 10 glomeruli were globally sclerosed. (c) IF showed 2-3+ IgG and C3 deposit mainly in mesangium and also along the capillary loops.
(d) Electron microscopy showed intramembranous and subepithelial electron dense deposits with occasional subendothelial and mesangial
deposits. There were segmental foot process effacement and focal mesangial interposition.

glomeruli showed mesangial proliferation and immune complex deposition consisting of IgG, IgM, and complement in
mesangial and endocapillary distribution. It was consistent
with immune mediated glomerulonephritis (Figure 1). Skin
biopsy of the rash was consistent with leukocytoclastic
vasculitis.
Given the clinical, laboratory, and pathologic findings,
we concluded that the ANCA associated systemic vasculitis
and immune complex mediated glomerulonephritis were
secondary to levamisole/cocaine use.

3. Clinical Course
He required mechanical ventilation for acute hypoxic and
hypercarbic respiratory failure. He was placed on continuous
renal replacement therapy for severe azotemia with multiple
electrolyte abnormalities including hyperkalemia. He was
started on high dose steroids with marked improvement in
his rash, mucocutaneous lesions, and arthritis. There was no
renal recovery and he remained hemodialysis dependent. He
was discharged on prednisone 40 mg daily, slowly tapered,
and stopped after 3 months with resolution of arthritis and
skin rash. Repeat rheumatologic workup was negative for
ANCA after 3 months of steroid therapy and cocaine abstinence. He is currently undergoing intermittent hemodialysis
and is awaiting renal transplant.

4. Discussion
Levamisole contamination of cocaine has become a widespread health problem. In 2009, nearly two-thirds of cocaine
samples seized by the DEA in the US [5] were found to be
contaminated with levamisole. It is thought to potentiate the
psychotropic effect of the illicit drug by increasing dopamine
in the brain, acts as a bulking agent, and is morphologically
difficult to recognize as an adulterant. It continues to gain
medical attention as more and more cases of adverse effects
of levamisole are being reported.
Earliest cases of levamisole induced necrotizing cutaneous vasculitis were reported in 1970s by Scheinberg et al.
and Macfarlane and Bacon [3, 4]. Segal et al. reported levamisole induced arthritis in patients treated with levamisole
as immunomodulator for Crohn’s disease [6]. Strazzula et al.
reported multiple cases of purpuric skin lesions in levamisole
exposed patients that required less aggressive strategies than
what is used for primary ANCA associated vasculitis [7].
Most of these patients tested positive for anticardiolipin
antibodies, ANA, p-ANCA, or c-ANCA, all of which resolved
after drug withdrawal.
Cocaine itself has been associated with ANCA positive
cutaneous vasculitis but systemic organs are rarely affected
[8, 9]. The contamination with levamisole adds an additional
compounding factor and toxicity can occur with snorting,
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smoking, or intravenous use. Most of the affected individuals
are chronic, habitual users suggesting large cumulative, dose
dependent response [10–14].
First description of levamisole induced nephropathy was
as early as in 1978 when Hansen et al. described a case of
rheumatoid arthritis treated with levamisole developing a
pruritic rash, leukopenia, thrombocytopenia, and proteinuria
[15]. Kidney biopsy revealed granular mesangial deposits of
IgA, IgG, IgM, and C3. Zwang et al. described a similar
presentation with arthritis, neutropenia, purpuric rash, and
acute kidney injury that had also urinalysis consistent with
proteinuria but no red blood cells or cast [16]. Dı́az et al. also
reported cutaneous vasculitis, leukopenia, renal failure, and
nephrotic proteinuria in their patient abusing intravenous
cocaine [17]. Unfortunately no renal biopsies were performed
in these patients. McGrath et al. in their case series of 30
patients with ANCA positivity associated with levamisolecontaminated cocaine use found 8 patients to have abnormal urinalysis with dipstick proteinuria, hematuria, or the
presence of cellular casts on microscopy [18]. Two of these
developed severe acute kidney injury and one underwent
renal biopsy; however, that revealed pauci-immune focal
necrotizing and crescentic glomerulonephritis. The mechanism in the pathogenesis of levamisole/cocaine induced
ANCA positive systemic vasculitis and immune complex
glomerulonephritis is unclear.
Renal involvement is relatively uncommon with ANCA
positive vasculitis caused by levamisole/cocaine. To the
best of our knowledge, this may be the second reported case
with biopsy proven immune complex mediated glomerulonephritis. Rheumatologic workup in our patient was
positive for atypical p-ANCA, myeloperoxidase antibody,
and hypocomplementemia. In the presence of adequate exposure, these abnormalities are now increasingly recognized
as very specific for levamisole-adulterated cocaine exposure
[18–20].

5. Conclusion
This case illustrates the growing issue of cocaine abuse and
levamisole contamination. Levamisole induced vasculitis is a
diagnosis of exclusion but should be considered in cocaine
users presenting with vasculitis, arthralgia, leukopenia, and
positive ANCA titers after excluding infections and other
idiopathic vasculitides. Timely recognition of this clinical
entity is important to avoid misdiagnosis and unnecessary
prolonged treatment with harmful cytotoxic agents as discontinuation of cocaine use could result in resolution of
symptoms.
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